Volastra Therapeutics' oral KIF18A inhibitor VLS-1488 demonstrated tumor reduction in 7 of 17 heavily pre-treated advanced ovarian cancer patients in a Phase I/II trial, with preliminary data to be presented at the 2025 ASCO Annual Meeting.
The FDA has granted Fast Track designation to VLS-1488, a KIF18A inhibitor developed by Volastra Therapeutics, for treating platinum-resistant high-grade serous ovarian cancer (HGSOC).
Volastra Therapeutics has dosed the first patient in a Phase Ib trial evaluating sovilnesib for platinum-resistant or refractory high-grade serous ovarian cancer, with the FDA granting Fast Track designation for this indication.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.